Lbp Am Sa Buys 5,085 Shares of BioNTech SE (NASDAQ:BNTX)

Lbp Am Sa boosted its stake in shares of BioNTech SE (NASDAQ:BNTX) by 2.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 252,918 shares of the company’s stock after purchasing an additional 5,085 shares during the period. Lbp Am Sa owned about 0.11% of BioNTech worth $28,820,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Fred Alger Management LLC bought a new position in BioNTech during the third quarter valued at approximately $59,485,000. Charles Schwab Investment Management Inc. lifted its position in BioNTech by 123.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 134,036 shares of the company’s stock valued at $15,919,000 after purchasing an additional 74,119 shares during the period. SG Americas Securities LLC lifted its position in BioNTech by 412.3% during the fourth quarter. SG Americas Securities LLC now owns 41,470 shares of the company’s stock valued at $4,726,000 after purchasing an additional 33,375 shares during the period. Mirabaud & Cie SA bought a new position in BioNTech during the fourth quarter valued at approximately $684,000. Finally, Redmile Group LLC bought a new position in BioNTech during the third quarter valued at approximately $18,345,000. Institutional investors own 15.52% of the company’s stock.

BioNTech Price Performance

BNTX stock opened at $97.46 on Friday. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The company has a fifty day simple moving average of $116.18 and a two-hundred day simple moving average of $113.04. The firm has a market capitalization of $23.37 billion, a P/E ratio of -46.41 and a beta of 0.30.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, March 10th. The company reported $1.08 EPS for the quarter, beating the consensus estimate of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. During the same quarter last year, the business earned $1.90 earnings per share. BioNTech’s quarterly revenue was down 19.5% compared to the same quarter last year. Analysts anticipate that BioNTech SE will post -3.88 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on BNTX. HC Wainwright reaffirmed a “buy” rating and set a $150.00 target price on shares of BioNTech in a report on Monday, November 18th. BMO Capital Markets upped their target price on shares of BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a report on Tuesday. JPMorgan Chase & Co. reduced their target price on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating for the company in a report on Tuesday, November 26th. Citigroup began coverage on shares of BioNTech in a report on Thursday. They set a “buy” rating and a $145.00 target price for the company. Finally, Evercore ISI raised shares of BioNTech from an “in-line” rating to an “outperform” rating and upped their target price for the company from $110.00 to $125.00 in a report on Tuesday, November 19th. Three equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $143.73.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.